Hemophilia and Bleeding Disorders Program Research

A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems.

Using an innovative gene therapy technique called genome editing that hones in on the precise location of mutated DNA, scientists have treated hemophilia, a blood clotting disorder, in mice.